Latest news and press releases about Fractyl Health, Inc. (GUTS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Price
| Price | $0.56 |
| Market Cap | $89M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -52.73 |
| EV / EBITDA | -1.19 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -1625.88% |
| Return on Invested Capital | -120.27% |
| Return on Assets | -128.88% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADVM · ALXO · ARTV · ATYR · BMEA · DTIL · MGX
Explore sector: Healthcare · Biotechnology
More sections of GUTS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks